Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain?

Year: 2021

Publisher: Gynecologic Oncology

Abstract: Ovarian carcinoma (OC) has one of the highest mortality rates of gynecologic cancer in women. In Spain, 3,645 incident patients are expected to be diagnosed in 2020, an increase of 2.7% over those diagnosed last year.

The objective presented in this study was to estimate the cost-effectiveness of Olaparib after being funded by the National Health Service (NHS) as first-line maintenance treatment in monotherapy in patients with advanced high-grade serous ovarian carcinoma of the ovary (HGSOC) and BRCA mutations in Spain.

A semi-Markov model with one-month cycles was adapted to the Spanish healthcare setting, using the SNHS perspective and a 50-year time horizon.

The authors would like to thank Rob Hettle for developing the model for the United Kingdom that served as the basis for conducting this research.

Keywords: Ovarian carcinoma, BRCA mutations, Olaparib, SOLO1, Cost-effectiveness analysis, Cost-utility analysis

How to cite: C. Moya-Alarcón, A. González-Domínguez, Y. Ivanova-Markova, et al., Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain?, Gynecologic Oncology, https://doi.org/10.1016/j.ygyno.2021.11.011